Converging evidence from primary tumors, patient-derived xenografts, cell lines, and genetically engineered mouse models has led to the identification of a novel SCLC subtype classification based on the differential expression of four key transcription factors: ASCL1, NeuroD1, Yap1, and POU2F3 (2). This evidence concerns the gene NEUROD1 and small cell lung carcinoma.